Detail akcie Heron Therapeutics online

Business Summary: Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Heron Therapeutics Inc revenues increased 14% to $144.3M. Net loss decreased 88% to $13.6M. Revenues reflect ZYNRELEF segment increase of 44% to $25.5M, CINVANTI segment increase of 5% to $100.1M, APONVIE segment increase from $1.4M to $4.5M. Lower net loss reflects United States segment loss decrease of 90% to $11.5M.